References
Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K et al (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82:410–426
Kasel D, Harlfinger S, Kinzig-Schippers M, Sörgel F, Gebhardt W, Fuhr U (2002) Determination of midazolam in human plasma using LC-MS/MS devices from two different manufacturers. Eur J Clin Pharmacol 58:87
Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sörgel F, Klaassen T et al (2005) Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33:1859–1866
Conflict of interest statement
The authors declare no conflict of interest
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tomalik-Scharte, D., Doroshyenko, O., Kirchheiner, J. et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 64, 1033–1035 (2008). https://doi.org/10.1007/s00228-008-0503-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-008-0503-9